| Literature DB >> 30110920 |
Magdalena Timoszuk1, Katarzyna Bielawska2, Elżbieta Skrzydlewska3.
Abstract
Evening primrose (Oenothera L.) is a plant belonging to the family Onagraceae, in which the most numerous species is Oenothera biennis. Some plants belonging to the genus Oenothera L. are characterized by biological activity. Therefore, studies were conducted to determine the dependence of biological activity on the chemical composition of various parts of the evening primrose, mainly leaves, stems, and seeds. Common components of all parts of the Oenothera biennis plants are fatty acids, phenolic acids, and flavonoids. In contrast, primrose seeds also contain proteins, carbohydrates, minerals, and vitamins. Therefore, it is believed that the most interesting sources of biologically active compounds are the seeds and, above all, evening primrose seed oil. This oil contains mainly aliphatic alcohols, fatty acids, sterols, and polyphenols. Evening primrose oil (EPO) is extremely high in linoleic acid (LA) (70⁻74%) and γ-linolenic acid (GLA) (8⁻10%), which may contribute to the proper functioning of human tissues because they are precursors of anti-inflammatory eicosanoids. EPO supplementation results in an increase in plasma levels of γ-linolenic acid and its metabolite dihomo-γ-linolenic acid (DGLA). This compound is oxidized by lipoxygenase (15-LOX) to 15-hydroxyeicosatrienoic acid (15-HETrE) or, under the influence of cyclooxygenase (COX), DGLA is metabolized to series 1 prostaglandins. These compounds have anti-inflammatory and anti-proliferative properties. Furthermore, 15-HETrE blocks the conversion of arachidonic acid (AA) to leukotriene A₄ (LTA₄) by direct inhibition of 5-LOX. In addition, γ-linolenic acid suppresses inflammation mediators such as interleukin 1β (IL-1β), interleukin 6 (IL-6), and cytokine - tumor necrosis factor α (TNF-α). The beneficial effects of EPO have been demonstrated in the case of atopic dermatitis, psoriasis, Sjögren's syndrome, asthma, and anti-cancer therapy.Entities:
Keywords: eicosanoids; evening primrose oil; linoleic acid; omega-6 fatty acids; γ-linolenic acid
Year: 2018 PMID: 30110920 PMCID: PMC6116039 DOI: 10.3390/antiox7080108
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Fatty acid composition of evening primrose oil (EPO) (Oenothera biennis L.) [8].
| Compound Name | Contents (%) |
|---|---|
| linoleic acid | 73.88 ± 0.09 |
| γ-linolenic acid | 9.24 ± 0.05 |
| oleic acid | 6.93 ± 0.02 |
| palmitic acid | 6.31 ± 0.14 |
| stearic acid | 1.88 ± 0.02 |
| vaccenic acid | 0.81 ± 0.03 |
| eicosenoic acid | 0.55 ± 0.01 |
| eicosanoic acid | 0.31 ± 0.03 |
| behenic acid | 0.10 ± 0.01 |
Phenolic acid composition (mg/kg) in Oenothera biennis L. seed [9].
| Acid Name | Included in | |||
|---|---|---|---|---|
| Free | Esters | Glycosides | Total | |
| n/a | 1.03 ± 0.18 | 0.26 ± 0.05 | 1.29 ± 0.19 | |
| 4.12 ± 0.25 | 0.38 ± 0.07 | 0.29 ± 0.10 | 4.79 ± 0.26 | |
| 2-hydroxy-4-methoxybenzoic | 6.52 ± 0.30 | n/a | 0.83 ± 0.28 | 7.35 ± 0.41 |
| caffeic | 6.48 ± 0.29 | 0.80 ± 0.14 | n/a | 7.51 ± 0.33 |
| hydroxycaffeic | n/a | 0.77 ± 0.18 | n/a | 0.77 ± 0.18 |
| 4.90 ± 0.45 | 0.83 ± 0.21 | n/a | 5.73 ± 0.50 | |
| 1.32 ± 0.10 | 1.96 ± 0.23 | 0.06 ± 0.06 | 3.34 ± 0.25 | |
| ferulic | 4.08 ± 0.30 | 0.72 ± 0.09 | 0.22 ± 0.06 | 5.02 ± 0.32 |
| gallic | 1.87 ± 0.22 | 7.03 ± 0.82 | 5.91 ± 1.56 | 14.81 ± 1.78 |
| protocatechuic | 50.28 ± 0.77 | 10.96 ± 0.34 | 2.16 ± 2.42 | 63.40 ± 2.56 |
| vanillic | 5.22 ± 0.28 | 0.06 ± 0.02 | 0.83 ± 0.28 | 7.35 ± 0.41 |
| veratric | n/a | 0.41 ± 0.03 | 0.47 ± 0.15 | 0.88 ± 0.15 |
| homoveratric | n/a | 0.43 ± 0.06 | n/a | 0.43 ± 0.06 |
| salicylic | 1.15 ± 0.04 | 1.40 ± 0.18 | n/a | 2.55 ± 0.18 |
n/a—not available.
Sterol content of EPO (Oenothera biennis L.) [8].
| Compound Name | Contents (mg/kg of Oil) |
|---|---|
| β-sitosterol | 7952.00 ± 342.25 |
| kampesterol | 883.32 ± 0.45 |
| Δ5-avenasterol | 429.65 ± 75.20 |
| sitostanol | 167.01 ± 39.77 |
| clerosterol | 120.44 ± 0.12 |
| Δ5-24-estigmastadienol | 94.60 ± 5.68 |
| Δ7-estigmasterol | 38.17 ± 14.33 |
| Δ7-avenasterol | 27.80 ± 16.07 |
Macroelements and microelements contributing to seed ash [10].
|
|
|
| calcium | 1800 |
| magnesium | 530 |
| potassium | 460 |
| sodium | 18 |
| phosphorus | 410 |
|
|
|
| iron | 39 |
| zinc | 7 |
| copper | 1.1 |
| manganese | 0.5 |
Biological effect and occurrence of selective eicosanoids [18,44,45].
| Metabolite | Biological Activity | Occurrence | |
|---|---|---|---|
|
| PGE1 |
anti-inflammatory anti-proliferatory | keratinocytes |
| 15-HETrE |
anti-inflammatory anti-proliferatory | keratinocytes | |
| 13-HODE |
anti-inflammatory anti-proliferatory | keratinocytes | |
| 15-HETE |
anti-inflammatory (lipoxin precursor) anti-proliferatory counteracts 12-HETE and LTB4 effects induces leukocyte chemotaxis | keratinocytes | |
| LXA4 |
anti-inflammatory LXA4 inhibits expression of interleukin 6 (IL-6) and interleukin 8 (IL-8) LXA4 inhibits proliferation | neutrophils | |
|
| PGE2 |
proliferatory chemotaxis immunosuppression | keratinocytes |
| 5-HETE |
chemotaxis | keratinocytes | |
| LTB4 |
chemotaxis | leukocytes | |
| Cys-LT |
leukocyte activators chemotaxis | leukocytes | |
| 12-HETE |
proliferatory chemotaxis | keratinocytes |
Cys-LT: cysteinyl leukotrienes; LTC4: leukotriene C4, LTD4: leukotriene D4; LTE4—leukotriene E4.
Figure 1Linoleic acid (LA) metabolism. 9-HODE: 9-hydroxyoctadecadienoic acid; 13-HODE: 13-hydroxyoctadecadienoic acid; 15-HETrE: 15-hydroxyeicosatrienoic; PGE1: prostaglandin E1; PGD1: prostaglandin D1; PLA2: phospholipase A2; PLC: phospholipase C; 5-HPETE: 5-hydroperoxyeicosatetraenoic acid; 5-HETE: 5-hydroxyeicosatetraenoic acid; LTA4: leukotriene A4; LTB4: leukotriene B4; LTC4: leukotriene C4; LTD4: leukotriene D4; LTE4: leukotriene E4; 15-HPETE: 15-hydroperoxyeicosatetraenoic acid; 15-HETE: 15-hydroxyeicosatetraenoic acid; LXA4: lipoxin A4; LXB4: lipoxin B4; 12-HPETE: 12-hydroperoxyeicosatetraenoic acid; 12-HETE: 12- hydroxyeicosatetraenoic acid: PGG2: prostaglandin G2; PGH2: prostaglandin H2; PGI2: prostaglandin I2: PGD2: prostaglandin D2; 15-d-PGJ2: 15-deoxy-delta-12,14-prostaglandin J2; PGE2: prostaglandin E2: PGF2: prostaglandin F2: TXA2: thromboxane A2; TXB2: thromboxane B2.